Media stories about Vermillion (NASDAQ:VRML) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vermillion earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave news stories about the company an impact score of 40.0033924364826 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Vermillion (NASDAQ:VRML) opened at 1.43 on Tuesday. The stock’s market capitalization is $80.21 million. Vermillion has a 12-month low of $0.76 and a 12-month high of $2.85. The stock has a 50 day moving average price of $1.76 and a 200 day moving average price of $1.81.

Vermillion (NASDAQ:VRML) last released its earnings results on Thursday, May 18th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.01. The business had revenue of $0.73 million during the quarter. Vermillion had a negative net margin of 443.29% and a negative return on equity of 195.68%. On average, equities analysts anticipate that Vermillion will post ($0.16) earnings per share for the current fiscal year.

Separately, ValuEngine raised Vermillion from a “sell” rating to a “hold” rating in a report on Friday, June 2nd.

TRADEMARK VIOLATION NOTICE: “Vermillion (NASDAQ:VRML) Receiving Somewhat Favorable News Coverage, Accern Reports” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at

Vermillion Company Profile

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Insider Buying and Selling by Quarter for Vermillion (NASDAQ:VRML)

Receive News & Stock Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related stocks with our FREE daily email newsletter.